143 related articles for article (PubMed ID: 22948869)
21. Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model.
Valentin A; Le Guennec R; Rodriguez E; Reynes J; Mallie M; Bastide JM
Antimicrob Agents Chemother; 1996 Jun; 40(6):1342-5. PubMed ID: 8725998
[TBL] [Abstract][Full Text] [Related]
22. Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Sinnollareddy MG; Roger C; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2016 Nov; 60(11):6550-6557. PubMed ID: 27550344
[TBL] [Abstract][Full Text] [Related]
23. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
Wasan KM; Conklin JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.
Louie A; Drusano GL; Banerjee P; Liu QF; Liu W; Kaw P; Shayegani M; Taber H; Miller MH
Antimicrob Agents Chemother; 1998 May; 42(5):1105-9. PubMed ID: 9593135
[TBL] [Abstract][Full Text] [Related]
26. ZD0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans.
Najvar LK; Correa A; James P; Luther MF; Graybill JR
J Antimicrob Chemother; 1996 Oct; 38(4):671-7. PubMed ID: 8937961
[TBL] [Abstract][Full Text] [Related]
27. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
Petraitiene R; Petraitis V; Groll AH; Candelario M; Sein T; Bell A; Lyman CA; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2148-55. PubMed ID: 10471556
[TBL] [Abstract][Full Text] [Related]
28. Plasma concentrations of fluconazole after a single oral dose and administration in drinking water in cockatiels (Nymphicus hollandicus).
Ratzlaff K; Papich MG; Flammer K
J Avian Med Surg; 2011 Mar; 25(1):23-31. PubMed ID: 21657184
[TBL] [Abstract][Full Text] [Related]
29. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates.
Holmes AR; Lin YH; Niimi K; Lamping E; Keniya M; Niimi M; Tanabe K; Monk BC; Cannon RD
Antimicrob Agents Chemother; 2008 Nov; 52(11):3851-62. PubMed ID: 18710914
[TBL] [Abstract][Full Text] [Related]
30. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.
Gharibian KN; Mueller BA
Clin Nephrol; 2016 Jul; 86(7):43-50. PubMed ID: 27251341
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.
Andes D; Marchillo K; Conklin R; Krishna G; Ezzet F; Cacciapuoti A; Loebenberg D
Antimicrob Agents Chemother; 2004 Jan; 48(1):137-42. PubMed ID: 14693531
[TBL] [Abstract][Full Text] [Related]
32. Interactions of a prenylated flavonoid from Dalea elegans with fluconazole against azole- resistant Candida albicans.
Barceló S; Peralta M; Calise M; Finck S; Ortega G; Diez RA; Cabrera JL; Pérez C
Phytomedicine; 2017 Aug; 32():24-29. PubMed ID: 28732804
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of fluconazole following intravenous and oral administration and body fluid concentrations of fluconazole following repeated oral dosing in horses.
Latimer FG; Colitz CM; Campbell NB; Papich MG
Am J Vet Res; 2001 Oct; 62(10):1606-11. PubMed ID: 11592327
[TBL] [Abstract][Full Text] [Related]
34. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
Louie A; Liu W; Miller DA; Sucke AC; Liu QF; Drusano GL; Mayers M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2831-40. PubMed ID: 10582868
[TBL] [Abstract][Full Text] [Related]
35. Liposomal thymoquinone effectively combats fluconazole-resistant Candida albicans in a murine model.
Khan MA; Aljarbou AN; Khan A; Younus H
Int J Biol Macromol; 2015 May; 76():203-8. PubMed ID: 25709021
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.
Cojutti PG; Lugano M; Righi E; Della Rocca G; Bassetti M; Hope W; Pea F
Eur J Clin Pharmacol; 2018 Nov; 74(11):1449-1459. PubMed ID: 30032414
[TBL] [Abstract][Full Text] [Related]
37. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection.
Lewis RE; Kontoyiannis DP; Darouiche RO; Raad II; Prince RA
Antimicrob Agents Chemother; 2002 Nov; 46(11):3499-505. PubMed ID: 12384356
[TBL] [Abstract][Full Text] [Related]
38.
Zhao M; Lepak AJ; VanScoy B; Bader JC; Marchillo K; Vanhecker J; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378706
[TBL] [Abstract][Full Text] [Related]
39. Biodistribution of free and encapsulated
de Assis DN; Araújo RS; Fuscaldi LL; Fernandes SOA; Mosqueira VCF; Cardoso VN
Biomed Pharmacother; 2018 Mar; 99():438-444. PubMed ID: 29665644
[TBL] [Abstract][Full Text] [Related]
40. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.
Pai MP; Turpin RS; Garey KW
Antimicrob Agents Chemother; 2007 Jan; 51(1):35-9. PubMed ID: 17101684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
